Norway· NO-ID_36CBBCAE-9334-42DD-A9CB-A3941355F342
Rukobia
A fostemsavir product containing fostemsavir, registered in Norway by ViiV Healthcare BV. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Fostemsavir is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AX29 (fostemsavir), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Fostemsavir · ATC J05AX29
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Fostemsavir
- Manufacturer
- ViiV Healthcare BV
- Country
- Norway (NO)
- ATC code
- J05AX29
- ATC class
- Fostemsavir
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_36CBBCAE-9334-42DD-A9CB-A3941355F342
- no_varenummer09264760NOK 40973
- gtin5054290000184
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
232 interactions on record for fostemsavir.
Graded by severity as the source publishes them — 42 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fostemsavir · interactions on record
232 records
- 42 severe
- 168 moderate
- 22 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fostemsavir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRukobiaViiV Healthcare BV
- CzechiaRUKOBIAViiV Healthcare BV, Amersfoort
- SwitzerlandRukobia 600 mg, RetardtablettenViiV Healthcare GmbH
- SpainRUKOBIA 600 MG COMPRIMIDOS DE LIBERACION PROLONGADAViiv Healthcare B.V.
- FranceRUKOBIA 600 mg, comprimé à libération prolongéeVIIV HEALTHCARE (PAYS-BAS)
- United KingdomRukobia 600mg modified-release tabletsViiV Healthcare UK Ltd
- IrelandRukobia 600 mg prolonged-release tabletsViiV Healthcare BV
- IcelandRukobiaViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Rukobia
- Liechtenstein · Rukobia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/052b0989-c56f-4cd2-a33a-a9707c2f85ea GET /v1/drugs/052b0989-c56f-4cd2-a33a-a9707c2f85ea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Depottablett",
"source": "fest",
"status": "A",
"atc_name": "Fostemsavir",
"merkevare_id": "ID_36CBBCAE-9334-42DD-A9CB-A3941355F342",
"name_form_strength": "Rukobia depottab 600 mg",
"prescription_group": "C"
}See everything about fostemsavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.